New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2012
16:04 EDTVRX, MRXValeant and Galderma agree on revised agreement terms
Valeant Pharmaceuticals (VRX) announced that the company has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms of the revised agreement, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and conditions Galderma currently supplies those products to Medicis Pharmaceutical Corporation (MRX). In addition, Valeant will make an upfront payment and a royalty to Galderma on sales of Sculptra. Among other things, the agreement provides for resolution of all claims asserted in Galderma's pending litigation relating to Valeant's acquisition of Medicis. In addition, Valeant will obtain North American rights to Emervel, a next generation family of hyaluronic acid dermal fillers that are specifically designed to provide both patient tolerability and long-lasting correction of facial lines, contouring and volume loss or lip enhancement. The terms of the agreement are subject to the closing of Valeant's pending acquisition of Medicis, which is expected to occur on December 11.
News For VRX;MRX From The Last 14 Days
Check below for free stories on VRX;MRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTVRXPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
07:19 EDTVRXValeant top pick in specialty pharmaceutical space, says Cantor
Subscribe for More Information
April 8, 2014
07:08 EDTVRXDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
April 7, 2014
14:09 EDTVRXSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use